Ticker Launch
Sign inTry it free

SPAC · Merger completed

Therapeutics Acquisition Corp. (d/b/a Research Alliance Corp. I)

Business combination with POINT Biopharma Inc.

Therapeutics Acquisition Corp. (d/b/a Research Alliance Corp. I) is a blank-check company (SPAC) that raised $118M in its initial public offering on Jul 9, 2020, listing on Nasdaq Capital Market. It completed its business combination with POINT Biopharma Inc. on Jun 30, 2021; the combined company is POINT Biopharma Global Inc. (PNT). Goodwin Procter advised the SPAC and White & Case advised the underwriters on the IPO.

POINT Biopharma Inc. is a radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands to fight cancer. It is the target of a business combination with Therapeutics Acquisition Corp, referred to as RACA.

Status
Merger completed
IPO date
Jul 9, 2020
IPO size
$118M
IPO exchange
Nasdaq Capital Market
Target
POINT Biopharma Inc.
Announced
Mar 15, 2021
Closed
Jun 30, 2021
Combined company
POINT Biopharma Global Inc. (PNT)
SPAC counsel (IPO)
Goodwin Procter
Underwriters' counsel (IPO)
White & Case

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021